$15.26
+
$0.19 (1.25%)
End-of-day quote: 05/16/2024
ASX:CUV
Clinuvel Pharmaceuticals Profile
Clinuvel Pharmaceuticals Limited focuses on the development and commercialization of afamelanotide, its proprietary photoprotective drug. The company is testing the drug in five separate categories of patients, who suffer from light related skin disorders.
Country
Industry:
Biological Products, Except Diagnostic Substances
Founded:
1987
IPO Date:
02/13/2001
ISIN Number:
I_AU000000CUV3
Contact Details
Address:
535 Bourke Street, Level 22, Melbourne, Victoria, 3000, Australia
Phone Number
61 3 9660 4900
Key Executives
CEO:
Wolgen, Philippe
CFO
Keamy, Darren
COO:
Hay, Lachlan
